Compass Pathways plc (Nasdaq: CMPS) and Hackensack Meridian Health (HMH) have recently entered into a research collaboration agreement to enhance the design of the delivery model for investigational COMP360 psilocybin treatment, contingent on FDA approval. Compass, a biotechnology company dedicated to advancing patient access to evidence-based innovation in mental health, is partnering with HMH, a leading not-for-profit healthcare organization in New Jersey.

The collaborative effort aims to improve health outcomes and enhance the experiences of patients and providers dealing with mental health conditions, particularly treatment-resistant depression. Together, Compass and HMH will address real-world challenges and opportunities associated with delivering care to individuals with depression. This collaboration will inform the design of future clinical trials for COMP360 psilocybin treatment and provide insights into its potential delivery to patients.

COMP360 is Compass's proprietary formulation of synthetic psilocybin, administered alongside psychological support. Hackensack Meridian Health, with its 18 hospitals and over 500 patient care locations, offers a comprehensive range of medical services, innovative research, and life-enhancing care. Notably, the network boasts the only #1 ranked adult and children's hospitals in New Jersey, as per U.S. News & World Report, 2023-24.

Robert C. Garrett, CEO of Hackensack Meridian Health, expressed pride in collaborating with Compass Pathways, highlighting the significance of addressing challenging mental health conditions. The collaboration leverages HMH's leadership in mental health and extensive experience in treating depression in clinical practice to shape the accessibility of new mental health treatments for patients.

Kabir Nath, CEO of Compass Pathways, emphasized the collaboration's importance in understanding how COMP360 psilocybin treatment, if approved, could be effectively delivered to patients. He sees this collaboration with HMH, one of the largest and most integrated healthcare networks in the U.S., as a significant milestone in Compass's mission to offer improved treatment options for individuals in urgent need.

 

Source: globenewswire.com

Report Abuse